Last update Aug. 6, 2022

Mivacurium Chloride

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a non-depolarizing muscle relaxant drug with a peripheral action that is used as premedication for endotracheal intubation, general anesthesia and mechanical ventilation. Intravenous administración

Since the last update we have not found published data on its excretion in breastmilk.

Its moderately elevated molecular weight and very rapid half-life elimination period (under 2 minutes) make it highly unlikely that significant quantities will pass into breast milk. (Dalal 2014, Spigset 1994)

Also, quaternary ammonium muscle relaxants are poorly absorbed from the gastro-intestinal tract; its low oral bioavailability renders the pass of this agent to the infant's plasma highly unlikely. (Spigset 1994)

Mivacurium does not prevent a mother from breast feeding her baby shortly after recovering from anesthesia if she is awake and in good condition.

Alternatives

We do not have alternatives for Mivacurium Chloride since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Mivacurium Chloride in other languages or writings:

Group

Mivacurium Chloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Mivacurium Chloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 1.100 daltons
VD 0.1 - 0.2 l/Kg
0.02 - 0.03 hours

References

  1. Dalal PG, Bosak J, Berlin C. Safety of the breast-feeding infant after maternal anesthesia. Paediatr Anaesth. 2014 Abstract
  2. Atherton DP, Hunter JM. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clin Pharmacokinet. 1999 Abstract
  3. Ferriols Lisart R,Ferriols Lisart F. Farmacología clínica y usos terapéuticos del Mivacurio. Farm Hosp. 1997 Full text (in our servers)
  4. Spigset O. Anaesthetic agents and excretion in breast milk. Acta Anaesthesiol Scand. 1994 Abstract
  5. Frampton JE, McTavish D. Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia. Drugs. 1993 Abstract

Total visits

8,838

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM